Tumor stem cells (CD271, c-kit, SOX10) in melanomas: Prognostic and outcome implications

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 2, 2014, Pages 142-145

  Mohamed, Amr ^a   Gonzalez, Raul S ^a   Lawson, Diane ^a   Wang, Jason ^a   Cohen, Cynthia ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

melanoma; prognosis; tumor stem cells

Indexed keywords

ANTIGEN; CD271 ANTIGEN; TRANSCRIPTION FACTOR SOX10; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; DEATH; DESMOPLASTIC MELANOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALIGNANT LENTIGO; MELANOMA; METASTASIS; ONCOGENE C KIT; PRIORITY JOURNAL; SENTINEL LYMPH NODE; SPINDLE CELL; TISSUE MICROARRAY;

HUMANS; LYMPHATIC METASTASIS; MELANOMA; NAPHTHALENES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS; SOXE TRANSCRIPTION FACTORS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84896705923     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182910a3d     Document Type: Article

References (30)

1. Severi G, Giles GG, Robertson C, et al. Mortality From Cutaneous Melanoma: Evidence for Contrasting Trends Between Populations. Br J Cancer. 2000;82:1887-1891.
2. Hall HI, Miller DR, Rogers JD, et al. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol. 1999;40:35-42.
3. Jerant AF, Johnson JT, Sheridan CD, et al. Early detection and treatment of skin cancer. Am Fam Physician. 2000;62:357-368, 375-6, 381-2.
4. Scheier B, Amaria R, Lewis K, et al. Novel therapies in melanoma. Immunotherapy. 2011;3:1461-1469.
5. Kanavy HE, Gerstenblith MR. Ultraviolet radiation and melanoma. Semin Cutan Med Surg. 2011;30:222-228.
6. Narayanan DL, Saladi RN, Fox JL. Ultraviolet radiation and skin cancer. Int J Dermatol. 2010;49:978-986.
7. Sheffield MV, Yee H, Dorvault CC, et al. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol. 2002;118:930-936.
8. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol. 2002;20:1826-1831.
9. Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohisto-chemical characteristics of melanoma. J Cutan Pathol. 2008;35: 433-444.
10. Civenni G, Walter A, Kobert N, et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 2011;71:3098-3109.
11. Alexeev V, Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol. 2006;126:1102-1110.
12. Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007;43:935-946.
13. Rajaraman R, Guernsey DL, Rajaraman MM, et al. Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int. 2006;6:6-25.
14. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313-319.
15. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 2001;54:196-200.
16. Grichnik JM. Melanoma, nevogenesis, and stem cell biology. J Invest Dermatol. 2008;128:2365-2380.
17. Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res. 2008;21:39-55.
18. Cho RW, Clarke MF. Recent advances in cancer stem cells. Curr Opin Genet Dev. 2008;18:48-53.
19. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopu-lation with stem cell properties in melanomas. Cancer Res. 2005;65:9328-9337.
20. Boiko AD, Razorenova OV, van de Rijn M, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466:133-137.
21. Girouard SD, Murphy GF. Melanoma stem cells: not rare, but well done. Lab Invest. 2011;91:647-664.
22. Andre C, Hampe A, Lachaume P, et al. Sequence analysis of two genomic regions containing the KIT and the FMS receptor tyrosine kinase genes. Genomics. 1997;39:216-226.
23. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987;6:3341-3351.
24. de Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res. 2003;9:13-19.
25. Berdel WE, de Vos S, Maurer J, et al. Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene. Cancer Res. 1992;52:3498-3502.
26. Edling CE, Hallberg B. c-Kit-a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol. 2007;39:1995-1998.
27. Bondurand N, Kobetz A, Pingault V, et al. Expression of the SOX10 gene during human development. FEBS Lett. 1998;432: 168-172.
28. Mollaaghababa R, Pavan WJ. The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia. Oncogene. 2003;22:3024-3034.
29. Mohamed A, Gonzalez RS, Lawson D, et al. SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Appl Immuno-histochem Mol Morphol. 2012 [Epub ahead of print].
30. Pietra G. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol. 2009;21:793-801.